Together we invest in enabling personalized medicine for all
Multiplicom: Part of Agilent Technologies
On January 20, 2017, Agilent Technologies completed the acquisition of Multiplicom N.V., an innovator and a leading provider of simple, efficient and reliable molecular diagnostics solutions to collect genetic information for personalized treatment. With the completion of the acquisition, the Multiplicom team is now a part of the Genomics Division within Agilent’s Diagnostics & Genomics Group.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give their customers the highest confidence in their solutions.
Agilent focuses its expertise on six key markets, where they help their customers achieve their goals. These areas are Pharmaceutical, Diagnostics, Food, Environment and Forensics, Chemical and Energy, and Research.
Agilent’s Diagnostics and Genomics Group (DGG) leads Agilent’s efforts through the research to clinical continuum in the fields of cancer and inherited diseases. DGG comprises five Divisions: Genomics, Nucleic Acid Solutions, Pathology, Reagent Partnerships, and Companion Diagnostics. These Divisions collaborate to drive our strategy to fight cancer, improve the quality of life, enable new discoveries, and to form partnerships for novel therapeutics and diagnostics.